MX2022008342A - Metodos para tratar afecciones relacionadas con el receptor de s1p1. - Google Patents
Metodos para tratar afecciones relacionadas con el receptor de s1p1.Info
- Publication number
- MX2022008342A MX2022008342A MX2022008342A MX2022008342A MX2022008342A MX 2022008342 A MX2022008342 A MX 2022008342A MX 2022008342 A MX2022008342 A MX 2022008342A MX 2022008342 A MX2022008342 A MX 2022008342A MX 2022008342 A MX2022008342 A MX 2022008342A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- receptor
- conditions related
- treating conditions
- tetrahydrocyclopenta
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 208000004631 alopecia areata Diseases 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heat Treatment Of Sheet Steel (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Steering-Linkage Mechanisms And Four-Wheel Steering (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062957535P | 2020-01-06 | 2020-01-06 | |
| PCT/US2021/012367 WO2021142030A1 (en) | 2020-01-06 | 2021-01-06 | Methods of treating conditions related to the s1p1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008342A true MX2022008342A (es) | 2022-08-04 |
Family
ID=76788331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008342A MX2022008342A (es) | 2020-01-06 | 2021-01-06 | Metodos para tratar afecciones relacionadas con el receptor de s1p1. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230338336A1 (enExample) |
| EP (1) | EP4087562A4 (enExample) |
| JP (1) | JP2023509698A (enExample) |
| KR (1) | KR20220124209A (enExample) |
| CN (1) | CN115066242A (enExample) |
| AU (1) | AU2021205465A1 (enExample) |
| BR (1) | BR112022012846A2 (enExample) |
| CA (1) | CA3166828A1 (enExample) |
| IL (1) | IL294071A (enExample) |
| MX (1) | MX2022008342A (enExample) |
| TW (1) | TW202135804A (enExample) |
| WO (1) | WO2021142030A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240065283A (ko) * | 2021-09-23 | 2024-05-14 | 브리스톨-마이어스 스큅 컴퍼니 | Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법 |
| WO2023135506A1 (en) * | 2022-01-13 | 2023-07-20 | Arena Pharmaceuticals, Inc. | Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment |
| KR102541577B1 (ko) | 2022-10-21 | 2023-06-13 | 주식회사 넥스트젠바이오사이언스 | S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1469863A2 (en) * | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| CN104311472B9 (zh) * | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| PL2498610T5 (pl) * | 2009-11-13 | 2024-11-04 | Receptos Llc | Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej |
| HUE036391T2 (hu) * | 2009-11-13 | 2018-07-30 | Celgene Int Ii Sarl | Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások |
| CN105130922A (zh) * | 2009-11-13 | 2015-12-09 | 瑞塞普托斯公司 | 选择性的杂环1-磷酸鞘氨醇受体调节剂 |
| US9198911B2 (en) * | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| CA3002540C (en) * | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| CN110520124A (zh) * | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
-
2021
- 2021-01-06 WO PCT/US2021/012367 patent/WO2021142030A1/en not_active Ceased
- 2021-01-06 IL IL294071A patent/IL294071A/en unknown
- 2021-01-06 JP JP2022541198A patent/JP2023509698A/ja active Pending
- 2021-01-06 US US17/790,632 patent/US20230338336A1/en not_active Abandoned
- 2021-01-06 BR BR112022012846A patent/BR112022012846A2/pt not_active IP Right Cessation
- 2021-01-06 TW TW110100496A patent/TW202135804A/zh unknown
- 2021-01-06 KR KR1020227026729A patent/KR20220124209A/ko not_active Withdrawn
- 2021-01-06 AU AU2021205465A patent/AU2021205465A1/en not_active Abandoned
- 2021-01-06 CA CA3166828A patent/CA3166828A1/en active Pending
- 2021-01-06 CN CN202180013704.0A patent/CN115066242A/zh not_active Withdrawn
- 2021-01-06 EP EP21738729.9A patent/EP4087562A4/en not_active Withdrawn
- 2021-01-06 MX MX2022008342A patent/MX2022008342A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115066242A (zh) | 2022-09-16 |
| IL294071A (en) | 2022-08-01 |
| TW202135804A (zh) | 2021-10-01 |
| KR20220124209A (ko) | 2022-09-13 |
| EP4087562A4 (en) | 2024-01-10 |
| JP2023509698A (ja) | 2023-03-09 |
| CA3166828A1 (en) | 2021-07-15 |
| US20230338336A1 (en) | 2023-10-26 |
| WO2021142030A1 (en) | 2021-07-15 |
| BR112022012846A2 (pt) | 2022-09-06 |
| EP4087562A1 (en) | 2022-11-16 |
| AU2021205465A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295536B2 (en) | Specific tryptamines for use in the treatment of mood disorders | |
| MX2021013711A (es) | Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado. | |
| MY201603A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| WO2005047244A3 (en) | Inhibition of fgfr3 and treatment of multiple myeloma | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| UA92453C2 (ru) | Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения | |
| TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| BR0214967A (pt) | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente | |
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
| BG108072A (en) | The use of epothilone derivatives for the treatment of refractory tumors | |
| SE9903997D0 (sv) | New compounds | |
| GB2352972A (en) | Use of dexmedetomidine for icu sedation | |
| MX2022006083A (es) | Metodos para tratar afecciones relacionadas con el receptor s1p1. | |
| IL162515A0 (en) | Substituted diketopiperazines as oxytocin antagonists | |
| BR112022012846A2 (pt) | Métodos de tratamento de condições relacionadas ao receptor s1p1 | |
| EP1458734A4 (en) | ISOINDIGO, INDIGO AND INDIRUBIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | |
| MX2021011224A (es) | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| EP1064966A3 (en) | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | |
| ATE225177T1 (de) | Verwendung von (+)mefloquine zur behandlung von malaria |